Crohn-betegség: vizsgálatok itt: Dél-Korea
23 of 30 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Where
- Daegu, Seoul
- Életkor
- 2 év to 17 év
- People
- 70 worldwide
- Run by
- Takeda
See details and how to joinNCT06405087 · EU 2023-508804-39-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Where
- Ansan-si, Busan, Daegu, Daejeon, Dongjak-gu, Haeundae-gu, Seoul, Suwon, Wŏnju
- Életkor
- 16 év to 80 év
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Busan, Daegu, Daejeon, Gangwon-do, Guri-si, Seoul
- Életkor
- 16 év to 80 év
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00 - 3. fázisTaking peopleA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Where
- Busan, Daegu, Seoul
- Életkor
- 2 év to 17 év
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00 - 3. fázisTaking peopleA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Where
- Seoul
- Életkor
- 3 év to 64 év
- People
- 196 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00 - 2/3. fázisTaking peopleA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Busan, Daegu, Daejeon, Dongdaemun-gu, Seongnam-si, Seoul, Suwon
- Életkor
- 18 év and over
- People
- 1092 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00 - 3. fázisTaking peopleA Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Busan, Daejeon, Ganggu, Seoul
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00 - 2. fázisTaking peopleA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Where
- Busan, Daegu, Seoul, Wŏnju
- Életkor
- 18 év to 75 év
- People
- 268 worldwide
- Run by
- Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Ansan-si, Daegu, Gwangju, Seoul
- Életkor
- 16 év to 80 év
- People
- 425 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00 - 3. fázisTaking peopleAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Ansan-si, Busan, Daegu, Daejeon, Gwangju, Seoul, Suwon
- Életkor
- 16 év to 80 év
- People
- 980 worldwide
- Run by
- Sanofi
See details and how to joinNCT07184931 - 3. fázisTaking peopleA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Busan, Gwangju, Seoul
- Életkor
- 16 év to 80 év
- People
- 751 worldwide
- Run by
- Sanofi
See details and how to joinNCT07184944 - 3. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Where
- Daegu, Seoul
- Életkor
- 2 év to 17 év
- People
- 110 worldwide
- Run by
- AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00 - 3. fázisTaking peopleA Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Where
- Deagu, Seoul
- Életkor
- 2 év to 19 év
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT04844606 - 3. fázisTaking peopleA Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Where
- Busan, Daegu, Seoul
- Életkor
- 2 év to 17 év
- People
- 90 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05509777 · EU 2024-511472-32-00 - 2. fázisTaking peopleStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Where
- Busan, Daegu, Daejeon, Seoul
- Életkor
- 18 év to 75 év
- People
- 590 worldwide
- Run by
- AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00 - 1. fázisTaking peopleA Phase 1 Study of ATORM-C in Patients With Crohn's Disease
- Where
- Seoul
- Életkor
- 19 év to 80 év
- People
- 18
- Run by
- ORGANOIDSCIENCES LTD.
See details and how to joinNCT07822087 - 3. fázisTaking peopleA Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- Where
- Daegu, Seoul
- Életkor
- 2 év to 17 év
- People
- 70 worldwide
- Run by
- Takeda
See details and how to joinNCT06100289 · EU 2023-503188-40-00 - 3. fázisTaking peopleA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- Where
- Busan, Daegu, Daejeon, Seoul, Suwon
- Életkor
- 18 év to 65 év
- People
- 396 worldwide
- Run by
- Takeda
See details and how to joinNCT06227910 · EU 2023-509391-42-00 - 2. fázisTaking peopleA Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- Where
- Haeundae, Wŏnju
- Életkor
- 18 év to 75 év
- People
- 192 worldwide
- Run by
- Takeda
See details and how to joinNCT06764615 · EU 2024-518914-18-00 - 3. fázisTaking peopleA Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Where
- Daegu, Incheon, Seoul
- Életkor
- 2 év to 17 év
- People
- 240 worldwide
- Run by
- Takeda
See details and how to joinNCT05442567 · EU 2023-509046-36-00 - 3. fázisTaking peopleA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Where
- Daegu, Incheon, Seongnam, Seoul
- Életkor
- 2 év to 17 év
- People
- 120 worldwide
- Run by
- Takeda
See details and how to joinNCT04779320 · EU 2023-509045-13-00 - 4. fázisTaking peopleTDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease
- Where
- Seoul
- Életkor
- 19 év to 80 év
- People
- 86
- Run by
- Asan Medical Center
See details and how to joinNCT06051253 - No phaseTaking peopleEfficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD
- Where
- Seoul
- Életkor
- 18 év to 100 év
- People
- 100
- Run by
- Asan Medical Center
See details and how to joinNCT06064864